IDEAYA Biosciences, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Symbol
IDYA on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
17 Feb 2026

Latest SEC snapshot (2026-02-13) highlights Return On Equity -10.9%, Return On Assets -10.2%, and Current Ratio 11.34x.

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

25.8/100

Weak Confidence low

Return On Equity

-11%

Metric score 0.0/100

Return On Assets

-10%

Metric score 0.0/100

Financial Health

Current Ratio
11.34x

Strengths

NetIncomeLoss YoY

Watchpoints

Return On Equity, Return On Assets, and Current Ratio

Key metrics snapshot

Return On Equity

-11%

YoY: -67%

Industry median: -42% (n=671)

View history

Return On Assets

-10%

YoY: -67%

Industry median: -47% (n=669)

View history

Current Ratio

11.34x

YoY: -24%

Industry median: 3.43x (n=666)

View history

NetIncomeLoss YoY

59%

YoY:

Industry median: 0.36% (n=639)

View history

Profitability

Metric Latest value YoY change
Return On Equity -11% -67%
Return On Assets -10% -67%

Financial Health

Metric Latest value YoY change
Current Ratio 11.34x -24%
Debt-to-equity 0.08x +76%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY 59%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 87,814,027 +0.32%
Common Stock, Shares, Outstanding 87,796,561 +1.5%
Common Stock, Value, Issued $9,000 0%
Weighted Average Number of Shares Outstanding, Basic 88,485,238 +8.3%
Weighted Average Number of Shares Outstanding, Diluted 88,485,238 +8.3%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $314,704,000 +6.8%
General and Administrative Expense $63,319,000 +61%
Operating Income (Loss) $159,313,000 +51%
Nonoperating Income (Expense) $45,615,000 -13%
Earnings Per Share, Basic -1.28 +62%
Earnings Per Share, Diluted -1.28 +62%
Cash and Cash Equivalents, at Carrying Value $112,825,000 +34%
Marketable Securities, Current $526,563,000 -11%
Assets, Current $666,727,000 -3.3%
Property, Plant and Equipment, Net $8,217,000 -8.4%
Operating Lease, Right-of-Use Asset $23,068,000 +23%
Assets $1,109,324,000 -1.3%
Accounts Payable, Current $17,584,000 +14%
Employee-related Liabilities, Current $11,198,000 +36%
Accrued Liabilities, Current $40,892,000 +35%
Liabilities, Current $58,815,000 +28%
Operating Lease, Liability, Noncurrent $27,575,000 +46%
Liabilities $86,390,000 +33%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,267,000 +179%
Retained Earnings (Accumulated Deficit) $736,539,000 -18%
Stockholders' Equity Attributable to Parent $1,022,934,000 -3.4%
Liabilities and Equity $1,109,324,000 -1.3%
Common Stock, Shares Authorized 300,000,000 0%
Common Stock, Shares, Issued 87,796,561 +1.5%
Common Stock, Par or Stated Value Per Share 0.0001 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $113,840,000 +34%
Deferred Tax Assets, Valuation Allowance $196,405,000 +19%
Deferred Tax Assets, Gross $201,341,000 +19%
Operating Lease, Liability $27,914,000 +46%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $112,243,000 +59%
Lessee, Operating Lease, Liability, to be Paid $46,358,000 +23%
Property, Plant and Equipment, Gross $22,473,000 +8.7%
Operating Lease, Liability, Current $339,000 +14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,379,000 +215%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,944,000 +404%
Operating Lease, Weighted Average Discount Rate, Percent 0.115 -8.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $18,444,000 -0.76%
Lessee, Operating Lease, Liability, to be Paid, Year Three $5,248,000 +20%
Deferred Tax Assets, Operating Loss Carryforwards $37,207,000 -0.84%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 10,000,000 0%
Unrecognized Tax Benefits $8,833,000 +49%
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,323,000 +26%
Preferred Stock, Shares Outstanding 0
Deferred Tax Assets, Net of Valuation Allowance $4,936,000 +21%
Share-based Payment Arrangement, Expense $46,115,000 +33%
Preferred Stock, Par or Stated Value Per Share 0.0001 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%